Hospira, Pfenex in deal for Lucentis biosimilar

Pfenex Inc. (NYSE-M:PFNX) jumped $1.10 (16%) to $8 on Tuesday after partnering with Hospira Inc. (NYSE:HSP) to collaborate on the development of

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE